Skip to content

Scilex Holding Company SCLX Free cash flow yield

Free cash flow yield at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
31.4%+10.0pp
Viatris logo
ViatrisVTRS
11.5%-6.8pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-9.3%-3.7pp
Opko Health logo
Opko HealthOPK
-20.1%+1.9pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-24.4%-252pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-13.1%+0.4pp

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

Based on trailing twelve months.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's free cash flow yield?
Scilex Holding Company (SCLX) reported free cash flow yield of 4.3% in Q4 2025.
What is the long-term trend for Scilex Holding Company's free cash flow yield?
Over 2 years (2021 to 2025), Scilex Holding Company's free cash flow yield has grown at a 45.6% compound annual growth rate (CAGR), from -2% to 4.3%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.